Sigilon hold hurts ahead of key haemophilia meeting
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Bristol’s buy moves it to the top of the sales charts
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
ACC 2021 – Esbriet could Pirouette into heart failure
The IPF drug shows surprising promise in heart failure with preserved ejection fraction.
Big pharma freshens up
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
